Skip to main content
. 2017 Aug 2;8(38):64303–64316. doi: 10.18632/oncotarget.19791

Figure 4.

Figure 4

The risk group stratification within each clinical stage in the primary cohort (a, all patients; b-c, stages) and in the validation cohort of the SCLC patents (d, all patients; e-f, stages) NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.